OTCMKTS:CPHRF Cipher Pharmaceuticals Q3 2015 Earnings Results & Report $9.61 -0.15 (-1.54%) As of 12:42 PM Eastern Cipher Pharmaceuticals missed analyst expectations on both earnings and revenue in its Q3 2015 results, released November 4, 2015. The company reported EPS of -$0.04 versus the $0.07 consensus estimate, while revenue of $8.46 million fell short of the $12.50 million estimate by $4.04 million. Research:Profile Earnings Announcement Details QuarterQ3 2015Report DateNovember 4, 2015 Cipher Pharmaceuticals EPS ResultsActual EPS-$0.04Consensus EPS $0.07Beat/MissMissed by -$0.11One Year Ago EPSN/AEPS Beat Rate1 of last 6 quartersCipher Pharmaceuticals Revenue ResultsActual Revenue$8.46 millionExpected Revenue$12.50 millionBeat/MissMissed by -$4.04 millionYoY Revenue GrowthN/AUpcoming EarningsCipher Pharmaceuticals' next earnings date is estimated for Thursday, November 12, 2026, based on past reporting schedules. Conference Call ResourcesCompany Profile Cipher Pharmaceuticals Q3 2015 Earnings FAQ Did Cipher Pharmaceuticals beat earnings estimates for Q3 2015? Cipher Pharmaceuticals (OTCMKTS:CPHRF) reported earnings of -$0.04 per share for Q3 2015, missing the consensus estimate of $0.07. The report was announced on Wednesday, November 4, 2015. What was Cipher Pharmaceuticals' revenue for Q3 2015? Cipher Pharmaceuticals reported revenue of $8.46 million for Q3 2015, against a consensus estimate of $12.50 million. When is Cipher Pharmaceuticals' next earnings date? Cipher Pharmaceuticals' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Cipher Pharmaceuticals on the company's earnings history page. Cipher Pharmaceuticals Earnings HeadlinesCipher Pharmaceuticals Receives Favourable Decision Confirming Arbitration AwardSeptember 1, 2026 | finance.yahoo.comCipher Pharmaceuticals Balances U.S. Strain With Epuris StrengthAugust 25, 2026 | theglobeandmail.comWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.November 10 at 1:00 AM | Porter & Company (Ad)Cipher Pharmaceuticals Inc (CPHRF) (Q2 2026) Earnings Call Highlights: Epuris Growth and ...August 12, 2026 | finance.yahoo.comCipher Pharmaceuticals Inc CPHRFAugust 4, 2026 | morningstar.comMCipher Pharmaceuticals and the pan-Canadian Pharmaceutical Alliance (pCPA) Sign Letter of Intent for Public Drug Plan Coverage of Epuris®July 6, 2026 | finance.yahoo.comSee More Cipher Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cipher Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cipher Pharmaceuticals and other key companies, straight to your email. Email Address About Cipher PharmaceuticalsCipher Pharmaceuticals (OTCMKTS:CPHRF) is a Canadian specialty pharmaceutical company focused primarily on developing, acquiring, and commercializing medicines for dermatology and other areas with unmet medical needs. The company’s business model emphasizes licensing and advancing differentiated prescription products rather than maintaining a broad, traditional drug-discovery operation. Cipher’s dermatology portfolio has included Epuris, an oral isotretinoin product used to treat severe acne, as well as products for conditions such as actinic keratosis and excessive facial hair. The company has also pursued opportunities to expand its portfolio through product acquisitions, licensing agreements, and regulatory development in selected markets. Cipher serves healthcare providers and patients primarily in Canada and the United States, with its commercial reach depending on the specific product and applicable regulatory approvals. The company is headquartered in Canada and has historically operated as a commercial-stage pharmaceutical business focused on specialized prescription therapies.View Cipher Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A $4 Billion Jolt: NRG Energy Powers Data Center AmbitionsD-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneRocket Lab's Record Backlog Could Fuel a Rebound, But Neutron Raises the StakesDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings? Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
